Back to Agenda
Session 6 Track C: Value of the Medical Science Liaison Role (MSL) Across the Product Life Cycle - From Early Trial Execution to Patent Expiry
Session Chair(s)
Jim Wilkinson, PHD
U.S. Medical Affairs Lead (Immunology & Payer), Medical Affairs & Evidence Gener, Argenx, United States
The value proposition of a function to the organization must be clear, aligned, and consistently communicated to both internal and external stakeholders. In this session, we will discuss the different roles and value the MSL can bring along the product life cycle. Specific examples will be provided of best practices when working with programs pre-approval, around the peri-launch timeframe, and those mature products approaching patent expiry. We will discuss effectively working with study operations and clinical development, CROs, early development, OL engagement, disease state education, ISS/ISTs, product launches, HEOR for mature products, and metrics across the life cycle.
Learning Objective : - Describe the value of field-based medical teams, in the context of different stages of product development, to benefit the whole organizationM/LI>
- Identify best practices in a highly-regulated environment and how to flex activities based upon the phase of the supported product or program
- Evaluate specific examples of functional value implemented in the field that support internal, as well as, external customers
Speaker(s)
Richard Swank, PHD
Founder, Scientific Engagement LLC, United States
Valerie Ann Stafford-Fox, MBA, MSN, RN
Associate Director, BioOncology Women's Health Medical Science Liaison Team, Genentech, A Member of the Roche Group, United States
Ralph Rewers, PHARMD
US Medical Science Liaison, Head, Abbvie, United States
Have an account?